HK1070826A1 - Fluorosiloxane matrix controlled diffusion drug delivery system - Google Patents

Fluorosiloxane matrix controlled diffusion drug delivery system

Info

Publication number
HK1070826A1
HK1070826A1 HK05103602A HK05103602A HK1070826A1 HK 1070826 A1 HK1070826 A1 HK 1070826A1 HK 05103602 A HK05103602 A HK 05103602A HK 05103602 A HK05103602 A HK 05103602A HK 1070826 A1 HK1070826 A1 HK 1070826A1
Authority
HK
Hong Kong
Prior art keywords
fluorosiloxane
delivery system
drug delivery
controlled diffusion
matrix controlled
Prior art date
Application number
HK05103602A
Other languages
English (en)
Inventor
Joseph C Salamone
Jay F Kunzler
Daniel M Ammon Jr
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of HK1070826A1 publication Critical patent/HK1070826A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/22—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen
    • C08G77/24—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen halogen-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
    • C08L83/04—Polysiloxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/14—Polysiloxanes containing silicon bound to oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/20—Polysiloxanes containing silicon bound to unsaturated aliphatic groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/70—Siloxanes defined by use of the MDTQ nomenclature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK05103602A 2002-06-19 2005-04-27 Fluorosiloxane matrix controlled diffusion drug delivery system HK1070826A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/175,716 US20040043067A1 (en) 2002-06-19 2002-06-19 Fluorosiloxane matrix controlled diffusion drug delivery systems
PCT/US2003/019026 WO2004000288A1 (en) 2002-06-19 2003-06-16 Fluorosiloxane matrix controlled diffusion drug delivery system

Publications (1)

Publication Number Publication Date
HK1070826A1 true HK1070826A1 (en) 2005-06-30

Family

ID=29999052

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05103602A HK1070826A1 (en) 2002-06-19 2005-04-27 Fluorosiloxane matrix controlled diffusion drug delivery system

Country Status (18)

Country Link
US (1) US20040043067A1 (zh)
EP (1) EP1515705B1 (zh)
JP (1) JP2005530842A (zh)
CN (1) CN1662227A (zh)
AU (1) AU2003238247A1 (zh)
BR (1) BR0311963A (zh)
CA (1) CA2489987A1 (zh)
CZ (1) CZ200537A3 (zh)
DE (1) DE60306379T2 (zh)
ES (1) ES2261947T3 (zh)
HK (1) HK1070826A1 (zh)
MX (1) MXPA04012897A (zh)
PL (1) PL375000A1 (zh)
RU (1) RU2307667C2 (zh)
TW (1) TW200404569A (zh)
UA (1) UA80433C2 (zh)
WO (1) WO2004000288A1 (zh)
ZA (1) ZA200409979B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504938A (ja) 2004-07-02 2008-02-21 レイザー，エリオット 治療媒体送出装置およびその送出装置を用いて治療媒体を眼に送り出す方法
US7544371B2 (en) * 2005-12-20 2009-06-09 Bausch + Lomb Incorporated Drug delivery systems
US20070148244A1 (en) * 2005-12-22 2007-06-28 Kunzler Jay F Drug delivery systems
US20070218103A1 (en) * 2006-03-15 2007-09-20 Bausch & Lomb Incorporated Rate controlled release of a pharmaceutical agent in a biodegradable device
US20070218104A1 (en) * 2006-03-15 2007-09-20 Bausch & Lomb Incorporation Rate controlled release of a pharmaceutical agent in a biodegradable device
NZ595623A (en) 2006-03-31 2013-01-25 Mati Therapeutics Inc A drug insert surrounded by a sheath to expose a polymer containing a drug to surrounding tissues or an eye
US7579021B2 (en) * 2006-09-27 2009-08-25 Bausch & Lomb Incorporated Drug delivery systems based on degradable cationic siloxanyl macromonomers
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
JP5411140B2 (ja) 2007-09-07 2014-02-12 キュー エル ティー インク． 涙管インプラントの検出
US20110091508A1 (en) 2007-10-05 2011-04-21 Interface Biologics ,Inc. Oligofluorinated cross-linked polymers and uses thereof
KR20110129869A (ko) * 2009-01-23 2011-12-02 큐엘티 인코포레이티드 하나 이상의 제제의 서방형 전달
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP3290024B1 (en) 2011-08-29 2019-04-17 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
CA1295941C (en) * 1985-08-16 1992-02-18 Rajan Bawa Sustained-release formulation comprising a hydrophobic polymer system
US4882377A (en) * 1988-09-21 1989-11-21 Dow Corning Corporation Low-viscosity pressure-adherent silicone elastomer compositions
US5321108A (en) * 1993-02-12 1994-06-14 Bausch & Lomb Incorporated Fluorosilicone hydrogels
US5463010A (en) * 1993-11-12 1995-10-31 Surface Engineering Technologies, Division Of Innerdyne, Inc. Hydrocyclosiloxane membrane prepared by plasma polymerization process
US6322815B1 (en) * 1994-07-22 2001-11-27 W. Mark Saltzman Multipart drug delivery system
WO1997020851A1 (en) * 1995-12-07 1997-06-12 Bausch & Lomb Incorporated Monomeric units useful for reducing the modulus of low water polymeric silicone compositions
CN1084335C (zh) * 1995-12-07 2002-05-08 博士伦公司 用于降低硅氧烷水凝胶的模量的单体单元
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
ATE279461T1 (de) * 1997-04-03 2004-10-15 Guilford Pharm Inc Bioabbaubare terephthalat polyester-polyphosphat polymere, zusammensetzungen, gegenstände und verfahren für ihre herstellung und verwendung
US5908996A (en) * 1997-10-24 1999-06-01 Timewarp Technologies Ltd Device for controlling a musical performance
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
TW200404569A (en) 2004-04-01
CN1662227A (zh) 2005-08-31
EP1515705B1 (en) 2006-06-21
DE60306379T2 (de) 2007-06-14
ZA200409979B (en) 2006-07-26
UA80433C2 (en) 2007-09-25
US20040043067A1 (en) 2004-03-04
CA2489987A1 (en) 2003-12-31
RU2005100840A (ru) 2005-07-10
CZ200537A3 (cs) 2006-04-12
BR0311963A (pt) 2005-03-29
EP1515705A1 (en) 2005-03-23
RU2307667C2 (ru) 2007-10-10
MXPA04012897A (es) 2005-03-31
DE60306379D1 (de) 2006-08-03
JP2005530842A (ja) 2005-10-13
ES2261947T3 (es) 2006-11-16
WO2004000288A1 (en) 2003-12-31
PL375000A1 (en) 2005-11-14
AU2003238247A1 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
HK1070826A1 (en) Fluorosiloxane matrix controlled diffusion drug delivery system
GB2391480B (en) Drug delivery system
SI1631255T1 (sl) Sistem za razdeljevanje zdravil
PL372323A1 (en) Implantable drug delivery system
HUP0401438A3 (en) Drug delivery system
PL376169A1 (en) Drug delivery system
HUP0500795A2 (en) Gastric retention controlled drug delivery system
MXPA03009727A (es) SISTEMA DE SUMINISTRO DE FaRMACOS DE LIBERACIoN PROLONGADA QUE CONTIENE COFARMACOS.
EP1568359A4 (en) DRUG DELIVERY SYSTEM HAVING SUB-CONJUNCTIVAL DEPOSIT
HK1077523A1 (en) Proliposomal drug delivery system
IL169083A (en) Medication administration system
GB2385273B (en) Drug delivery device
IL159875A0 (en) Zero order controlled drug delivery system
EP1667619A4 (en) PHARMACEUTICAL FEEDING SYSTEM
AU2003212962A8 (en) Transdermal drug delivery systems
GB0103877D0 (en) Novel Drug Delivery system
AU2003231919A8 (en) Oral controlled drug delivery system containing carbamazepine
ZA200409726B (en) Monocompartment osmotic controlled drug delivery system.
AU2003285550A1 (en) Drug delivery system
AU2003269744A8 (en) Oral osmotic controlled drug delivery system
EP1509612A4 (en) TRANSCELLULAR DRUG DISPENSING SYSTEM
ZA200204331B (en) Pharmaceutical composition for controlled drug delivery system.
IL163614A0 (en) System for transvaginal drug delivery
GB2405094B (en) Pharmaceutical composition for controlled drug delivery system
GB0115136D0 (en) Drug delivery system

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100616